よむ、つかう、まなぶ。
資料２－２ 重篤副作用疾患別対応マニュアル 骨吸収抑制薬に関する顎骨壊死・顎骨骨髄炎（案）［6.1MB］ (37 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000209243_00011.html |
| 出典情報 | 重篤副作用総合対策検討会（第16回 10／17）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
12)Hata H, Imamachi K, et al : Prognosis by cancer type and incidence of zoledronic acidrelated osteonecrosis of the jaw: a single-center retrospective study Support Care Cancer
2022;30:4505–4514.
13)Kunihara T, Tohmori H, et al : Incidence and trend of antiresorptive agent-related
osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan. Osteoporos Int. 2023. doi:
10.1007/s00198-023-06732-8.
14)Ishimaru M, Ono S, et al : Prevalence, Incidence Rate, and Risk Factors of MedicationRelated Osteonecrosis of the Jaw in Patients With Osteoporosis and Cancer: A Nationwide
Population-Based Study in Japan. J Oral Maxillofac Surg 2022;80:714–727.
15)Qi WX, Tang LN, et al : Risk of osteonecrosis of the jaw in cancer patients receiving
denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol
2014;19:403–410.
16)Boquete-Castro A, Gómez-Moreno G, et al : Denosumab and osteonecrosis of the jaw. A
systematic analysis of events reported in clinical trials. Clin Oral Implants Res 2016;27:367–
375.
17)Saad F, Brown JE, et al : Incidence, risk factors, and outcomes of osteonecrosis of the jaw:
integrated analysis from three blinded active-controlled phase III trials in cancer patients with
bone metastases. Ann Oncol 2012;23:1341–1347.
18)Ehrenstein V, Heide-Jørgensen U, et al : Osteonecrosis of the jaw among patients with
cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort
postauthorization safety study in Denmark, Norway, and Sweden. Cancer 2021;127:4050–
4058.
19)Hallmer F, Bjarnadottir O, et al : Incidence of and risk factors for medication-related
osteonecrosis of the jaw in women with breast cancer with bone metastasis: a populationbased study. Oral Surg Oral Med Oral Pathol Oral Radiol 2020;130:252–257.
20)Loyson T, Van Cann T, et al : Incidence of osteonecrosis of the jaw in patients with bone
metastases treated sequentially with bisphosphonates and denosumab. Acta Clin Belg
2018;73:100–109.
21)Watts NB, Grbic JT, et al: Invasive Oral Procedures and Events in Postmenopausal
Women With Osteoporosis Treated With Denosumab for Up to 10 Years. J Clin Endocrinol
Metab. 2019;104:2443–2452.
22)Sugimoto T, Matsumoto T, et al : Three-year denosumab treatment in postmenopausal
36
2022;30:4505–4514.
13)Kunihara T, Tohmori H, et al : Incidence and trend of antiresorptive agent-related
osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan. Osteoporos Int. 2023. doi:
10.1007/s00198-023-06732-8.
14)Ishimaru M, Ono S, et al : Prevalence, Incidence Rate, and Risk Factors of MedicationRelated Osteonecrosis of the Jaw in Patients With Osteoporosis and Cancer: A Nationwide
Population-Based Study in Japan. J Oral Maxillofac Surg 2022;80:714–727.
15)Qi WX, Tang LN, et al : Risk of osteonecrosis of the jaw in cancer patients receiving
denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol
2014;19:403–410.
16)Boquete-Castro A, Gómez-Moreno G, et al : Denosumab and osteonecrosis of the jaw. A
systematic analysis of events reported in clinical trials. Clin Oral Implants Res 2016;27:367–
375.
17)Saad F, Brown JE, et al : Incidence, risk factors, and outcomes of osteonecrosis of the jaw:
integrated analysis from three blinded active-controlled phase III trials in cancer patients with
bone metastases. Ann Oncol 2012;23:1341–1347.
18)Ehrenstein V, Heide-Jørgensen U, et al : Osteonecrosis of the jaw among patients with
cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort
postauthorization safety study in Denmark, Norway, and Sweden. Cancer 2021;127:4050–
4058.
19)Hallmer F, Bjarnadottir O, et al : Incidence of and risk factors for medication-related
osteonecrosis of the jaw in women with breast cancer with bone metastasis: a populationbased study. Oral Surg Oral Med Oral Pathol Oral Radiol 2020;130:252–257.
20)Loyson T, Van Cann T, et al : Incidence of osteonecrosis of the jaw in patients with bone
metastases treated sequentially with bisphosphonates and denosumab. Acta Clin Belg
2018;73:100–109.
21)Watts NB, Grbic JT, et al: Invasive Oral Procedures and Events in Postmenopausal
Women With Osteoporosis Treated With Denosumab for Up to 10 Years. J Clin Endocrinol
Metab. 2019;104:2443–2452.
22)Sugimoto T, Matsumoto T, et al : Three-year denosumab treatment in postmenopausal
36